Performance of CHA₂DS₂-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.

ABSTRACT:

Aims

To compare the predictive performance of CHA₂DS₂-VASc and HAS-BLED scores in atrial fibrillation (AF) patients with and without cancer.

Methods and results

Using data from the Clinical Practice Research Datalink in England, we performed a retrospective cohort study of patients with new diagnoses of AF from 2009 to 2019. Cancer was defined as history of breast, prostate, colorectal, lung, or haematological cancer. We calculated the CHA₂DS₂-VASc and HAS-BLED scores for the 1-year risk of stroke and major bleeding events. Scores performance was estimated by discrimination [area under the receiver operating characteristic curve (AUC)] and calibration plots. Of 141 796 patients with AF, 10.3% had cancer. The CHA₂DS₂

SUBMITTER: Ajabnoor AM 

PROVIDER: S-EPMC11234295 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature